Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans
Statins were shown to inhibit borrelial growth in vitro and promote clearance of spirochetes in a murine model of Lyme borreliosis (LB). We investigated the impact of statin use in patients with early LB. In this post-hoc analysis, the association between statin use and clinical and microbiologic ch...
Gespeichert in:
| Veröffentlicht in: | PloS one 2021-12, Vol.16 (12), p.e0261194-e0261194 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e0261194 |
|---|---|
| container_issue | 12 |
| container_start_page | e0261194 |
| container_title | PloS one |
| container_volume | 16 |
| creator | Stupica, Daša Bajrović, Fajko F Blagus, Rok Cerar Kišek, Tjaša Collinet-Adler, Stefan Ružić-Sabljić, Eva Velušček, Maša |
| description | Statins were shown to inhibit borrelial growth in vitro and promote clearance of spirochetes in a murine model of Lyme borreliosis (LB). We investigated the impact of statin use in patients with early LB.
In this post-hoc analysis, the association between statin use and clinical and microbiologic characteristics was investigated in 1520 adult patients with early LB manifesting as erythema migrans (EM), enrolled prospectively in several clinical trials between June 2006 and October 2019 at a single-center university hospital. Patients were assessed at enrollment and followed for 12 months.
Statin users were older than patients not using statins, but statin use was not associated with Borrelia seropositivity rate, Borrelia skin culture positivity rate, or disease severity as assessed by erythema size or the presence of LB-associated symptoms. The time to resolution of EM was comparable in both groups. The odds for incomplete recovery decreased with time from enrollment, were higher in women, in patients with multiple EM, and in those reporting LB-associated symptoms at enrollment, but were unaffected by statin use.
Statin use was not associated with clinical and microbiologic characteristics or long-term outcome in early LB. |
| doi_str_mv | 10.1371/journal.pone.0261194 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_2610899942</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A687101227</galeid><doaj_id>oai_doaj_org_article_c8ab41efd26d4b4a9d19966dc93c1708</doaj_id><sourcerecordid>A687101227</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-5c4821c9d8eecd1cb918849d50b80b2159cdb57949a0f079603e3c998ba781553</originalsourceid><addsrcrecordid>eNqNk1trFDEUgAdRbK3-A9GAIArdNZlr8iIsxUuhUPD2GjLJmZmUTDImmdb9s_4Ws9tt7UofZB4yOfnO_Zwse07wkhQNeXfhZm-FWU7OwhLnNSGsfJAdElbkizrHxcM7_wfZkxAuMK4KWtePs4OiZKRsKnKY_V6F4KQWUTuLWohXABaFmO4WzQGQsApJo62WwiCZXAY4RqOW3rXaGddrieQgvJARvA5Ry3C81THO9oskG5Gbo3QjINchEN6s0dk63VrnPRjtgg5LtEKTCxENTiZdYdZJuMEn78IEMupL-BtD9FqY7bNQs4loSqGCjQFd6Tgg8Os4wChSiL0XNjzNHnUJh2e78yj7_vHDt5PPi7PzT6cnq7OFrFkeF5UsaU4kUxRAKiJbRigtmapwS3Gbk4pJ1VYNK5nAHW5YjQsoJGO0FQ0lVVUcZS-v7U7GBb5rTeCpK5gyxso8EafXhHLigk9ej8KvuROabwXO91z4VD8DXFLRlgQ6ldeqbEvBFGGsrpVkhSQNpsnW-523uR1ByZS_F2bP6P6L1QPv3SWndVM1FU4G3uwMePdzhhD5qIMEY4QFN2_jJnVVVOXG16t_0Puz21G9SAlo27nkV26M8lVNG4JJnjeJWt5DpU9BGqk0x51O8j2Ft3sKiYnwK_ZiDoGffv3y_-z5j3329R12AGHiEJyZN1sQ9sHyGkwDH4KH7rbIBPPNGt5Ug2_WkO_WMKm9uNugW6WbvSv-ABxkMrI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2610899942</pqid></control><display><type>article</type><title>Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Stupica, Daša ; Bajrović, Fajko F ; Blagus, Rok ; Cerar Kišek, Tjaša ; Collinet-Adler, Stefan ; Ružić-Sabljić, Eva ; Velušček, Maša</creator><contributor>Telford III, Sam R.</contributor><creatorcontrib>Stupica, Daša ; Bajrović, Fajko F ; Blagus, Rok ; Cerar Kišek, Tjaša ; Collinet-Adler, Stefan ; Ružić-Sabljić, Eva ; Velušček, Maša ; Telford III, Sam R.</creatorcontrib><description>Statins were shown to inhibit borrelial growth in vitro and promote clearance of spirochetes in a murine model of Lyme borreliosis (LB). We investigated the impact of statin use in patients with early LB.
In this post-hoc analysis, the association between statin use and clinical and microbiologic characteristics was investigated in 1520 adult patients with early LB manifesting as erythema migrans (EM), enrolled prospectively in several clinical trials between June 2006 and October 2019 at a single-center university hospital. Patients were assessed at enrollment and followed for 12 months.
Statin users were older than patients not using statins, but statin use was not associated with Borrelia seropositivity rate, Borrelia skin culture positivity rate, or disease severity as assessed by erythema size or the presence of LB-associated symptoms. The time to resolution of EM was comparable in both groups. The odds for incomplete recovery decreased with time from enrollment, were higher in women, in patients with multiple EM, and in those reporting LB-associated symptoms at enrollment, but were unaffected by statin use.
Statin use was not associated with clinical and microbiologic characteristics or long-term outcome in early LB.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0261194</identifier><identifier>PMID: 34914751</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Aged ; Animal models ; Antibiotics ; Antibodies ; Arachnids ; Biology and Life Sciences ; Biopsy ; Biosynthesis ; Borrelia ; Borrelia burgdorferi Group - drug effects ; Borrelia burgdorferi Group - isolation & purification ; Borreliosis ; Care and treatment ; Cholesterol ; Clinical trials ; Diagnosis ; Dosage and administration ; Enrollments ; Erythema ; Erythema Chronicum Migrans - drug therapy ; Erythema Chronicum Migrans - epidemiology ; Erythema Chronicum Migrans - microbiology ; Erythema Chronicum Migrans - pathology ; Female ; Follow-Up Studies ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage ; Immunology ; Infectious diseases ; Laboratories ; Lyme Disease - drug therapy ; Lyme Disease - epidemiology ; Lyme Disease - microbiology ; Lyme Disease - pathology ; Male ; Medical ethics ; Medicine ; Medicine and Health Sciences ; Middle Aged ; Patients ; Prospective Studies ; Research and Analysis Methods ; Signs and symptoms ; Skin - drug effects ; Skin - microbiology ; Skin - pathology ; Spirochetes ; Statins ; Testing</subject><ispartof>PloS one, 2021-12, Vol.16 (12), p.e0261194-e0261194</ispartof><rights>COPYRIGHT 2021 Public Library of Science</rights><rights>2021 Stupica et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2021 Stupica et al 2021 Stupica et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-5c4821c9d8eecd1cb918849d50b80b2159cdb57949a0f079603e3c998ba781553</citedby><cites>FETCH-LOGICAL-c692t-5c4821c9d8eecd1cb918849d50b80b2159cdb57949a0f079603e3c998ba781553</cites><orcidid>0000-0001-8927-2683</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675750/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8675750/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34914751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Telford III, Sam R.</contributor><creatorcontrib>Stupica, Daša</creatorcontrib><creatorcontrib>Bajrović, Fajko F</creatorcontrib><creatorcontrib>Blagus, Rok</creatorcontrib><creatorcontrib>Cerar Kišek, Tjaša</creatorcontrib><creatorcontrib>Collinet-Adler, Stefan</creatorcontrib><creatorcontrib>Ružić-Sabljić, Eva</creatorcontrib><creatorcontrib>Velušček, Maša</creatorcontrib><title>Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Statins were shown to inhibit borrelial growth in vitro and promote clearance of spirochetes in a murine model of Lyme borreliosis (LB). We investigated the impact of statin use in patients with early LB.
In this post-hoc analysis, the association between statin use and clinical and microbiologic characteristics was investigated in 1520 adult patients with early LB manifesting as erythema migrans (EM), enrolled prospectively in several clinical trials between June 2006 and October 2019 at a single-center university hospital. Patients were assessed at enrollment and followed for 12 months.
Statin users were older than patients not using statins, but statin use was not associated with Borrelia seropositivity rate, Borrelia skin culture positivity rate, or disease severity as assessed by erythema size or the presence of LB-associated symptoms. The time to resolution of EM was comparable in both groups. The odds for incomplete recovery decreased with time from enrollment, were higher in women, in patients with multiple EM, and in those reporting LB-associated symptoms at enrollment, but were unaffected by statin use.
Statin use was not associated with clinical and microbiologic characteristics or long-term outcome in early LB.</description><subject>Adult</subject><subject>Aged</subject><subject>Animal models</subject><subject>Antibiotics</subject><subject>Antibodies</subject><subject>Arachnids</subject><subject>Biology and Life Sciences</subject><subject>Biopsy</subject><subject>Biosynthesis</subject><subject>Borrelia</subject><subject>Borrelia burgdorferi Group - drug effects</subject><subject>Borrelia burgdorferi Group - isolation & purification</subject><subject>Borreliosis</subject><subject>Care and treatment</subject><subject>Cholesterol</subject><subject>Clinical trials</subject><subject>Diagnosis</subject><subject>Dosage and administration</subject><subject>Enrollments</subject><subject>Erythema</subject><subject>Erythema Chronicum Migrans - drug therapy</subject><subject>Erythema Chronicum Migrans - epidemiology</subject><subject>Erythema Chronicum Migrans - microbiology</subject><subject>Erythema Chronicum Migrans - pathology</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</subject><subject>Immunology</subject><subject>Infectious diseases</subject><subject>Laboratories</subject><subject>Lyme Disease - drug therapy</subject><subject>Lyme Disease - epidemiology</subject><subject>Lyme Disease - microbiology</subject><subject>Lyme Disease - pathology</subject><subject>Male</subject><subject>Medical ethics</subject><subject>Medicine</subject><subject>Medicine and Health Sciences</subject><subject>Middle Aged</subject><subject>Patients</subject><subject>Prospective Studies</subject><subject>Research and Analysis Methods</subject><subject>Signs and symptoms</subject><subject>Skin - drug effects</subject><subject>Skin - microbiology</subject><subject>Skin - pathology</subject><subject>Spirochetes</subject><subject>Statins</subject><subject>Testing</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1trFDEUgAdRbK3-A9GAIArdNZlr8iIsxUuhUPD2GjLJmZmUTDImmdb9s_4Ws9tt7UofZB4yOfnO_Zwse07wkhQNeXfhZm-FWU7OwhLnNSGsfJAdElbkizrHxcM7_wfZkxAuMK4KWtePs4OiZKRsKnKY_V6F4KQWUTuLWohXABaFmO4WzQGQsApJo62WwiCZXAY4RqOW3rXaGddrieQgvJARvA5Ry3C81THO9oskG5Gbo3QjINchEN6s0dk63VrnPRjtgg5LtEKTCxENTiZdYdZJuMEn78IEMupL-BtD9FqY7bNQs4loSqGCjQFd6Tgg8Os4wChSiL0XNjzNHnUJh2e78yj7_vHDt5PPi7PzT6cnq7OFrFkeF5UsaU4kUxRAKiJbRigtmapwS3Gbk4pJ1VYNK5nAHW5YjQsoJGO0FQ0lVVUcZS-v7U7GBb5rTeCpK5gyxso8EafXhHLigk9ej8KvuROabwXO91z4VD8DXFLRlgQ6ldeqbEvBFGGsrpVkhSQNpsnW-523uR1ByZS_F2bP6P6L1QPv3SWndVM1FU4G3uwMePdzhhD5qIMEY4QFN2_jJnVVVOXG16t_0Puz21G9SAlo27nkV26M8lVNG4JJnjeJWt5DpU9BGqk0x51O8j2Ft3sKiYnwK_ZiDoGffv3y_-z5j3329R12AGHiEJyZN1sQ9sHyGkwDH4KH7rbIBPPNGt5Ug2_WkO_WMKm9uNugW6WbvSv-ABxkMrI</recordid><startdate>20211216</startdate><enddate>20211216</enddate><creator>Stupica, Daša</creator><creator>Bajrović, Fajko F</creator><creator>Blagus, Rok</creator><creator>Cerar Kišek, Tjaša</creator><creator>Collinet-Adler, Stefan</creator><creator>Ružić-Sabljić, Eva</creator><creator>Velušček, Maša</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8927-2683</orcidid></search><sort><creationdate>20211216</creationdate><title>Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans</title><author>Stupica, Daša ; Bajrović, Fajko F ; Blagus, Rok ; Cerar Kišek, Tjaša ; Collinet-Adler, Stefan ; Ružić-Sabljić, Eva ; Velušček, Maša</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-5c4821c9d8eecd1cb918849d50b80b2159cdb57949a0f079603e3c998ba781553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Animal models</topic><topic>Antibiotics</topic><topic>Antibodies</topic><topic>Arachnids</topic><topic>Biology and Life Sciences</topic><topic>Biopsy</topic><topic>Biosynthesis</topic><topic>Borrelia</topic><topic>Borrelia burgdorferi Group - drug effects</topic><topic>Borrelia burgdorferi Group - isolation & purification</topic><topic>Borreliosis</topic><topic>Care and treatment</topic><topic>Cholesterol</topic><topic>Clinical trials</topic><topic>Diagnosis</topic><topic>Dosage and administration</topic><topic>Enrollments</topic><topic>Erythema</topic><topic>Erythema Chronicum Migrans - drug therapy</topic><topic>Erythema Chronicum Migrans - epidemiology</topic><topic>Erythema Chronicum Migrans - microbiology</topic><topic>Erythema Chronicum Migrans - pathology</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage</topic><topic>Immunology</topic><topic>Infectious diseases</topic><topic>Laboratories</topic><topic>Lyme Disease - drug therapy</topic><topic>Lyme Disease - epidemiology</topic><topic>Lyme Disease - microbiology</topic><topic>Lyme Disease - pathology</topic><topic>Male</topic><topic>Medical ethics</topic><topic>Medicine</topic><topic>Medicine and Health Sciences</topic><topic>Middle Aged</topic><topic>Patients</topic><topic>Prospective Studies</topic><topic>Research and Analysis Methods</topic><topic>Signs and symptoms</topic><topic>Skin - drug effects</topic><topic>Skin - microbiology</topic><topic>Skin - pathology</topic><topic>Spirochetes</topic><topic>Statins</topic><topic>Testing</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stupica, Daša</creatorcontrib><creatorcontrib>Bajrović, Fajko F</creatorcontrib><creatorcontrib>Blagus, Rok</creatorcontrib><creatorcontrib>Cerar Kišek, Tjaša</creatorcontrib><creatorcontrib>Collinet-Adler, Stefan</creatorcontrib><creatorcontrib>Ružić-Sabljić, Eva</creatorcontrib><creatorcontrib>Velušček, Maša</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stupica, Daša</au><au>Bajrović, Fajko F</au><au>Blagus, Rok</au><au>Cerar Kišek, Tjaša</au><au>Collinet-Adler, Stefan</au><au>Ružić-Sabljić, Eva</au><au>Velušček, Maša</au><au>Telford III, Sam R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2021-12-16</date><risdate>2021</risdate><volume>16</volume><issue>12</issue><spage>e0261194</spage><epage>e0261194</epage><pages>e0261194-e0261194</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Statins were shown to inhibit borrelial growth in vitro and promote clearance of spirochetes in a murine model of Lyme borreliosis (LB). We investigated the impact of statin use in patients with early LB.
In this post-hoc analysis, the association between statin use and clinical and microbiologic characteristics was investigated in 1520 adult patients with early LB manifesting as erythema migrans (EM), enrolled prospectively in several clinical trials between June 2006 and October 2019 at a single-center university hospital. Patients were assessed at enrollment and followed for 12 months.
Statin users were older than patients not using statins, but statin use was not associated with Borrelia seropositivity rate, Borrelia skin culture positivity rate, or disease severity as assessed by erythema size or the presence of LB-associated symptoms. The time to resolution of EM was comparable in both groups. The odds for incomplete recovery decreased with time from enrollment, were higher in women, in patients with multiple EM, and in those reporting LB-associated symptoms at enrollment, but were unaffected by statin use.
Statin use was not associated with clinical and microbiologic characteristics or long-term outcome in early LB.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>34914751</pmid><doi>10.1371/journal.pone.0261194</doi><tpages>e0261194</tpages><orcidid>https://orcid.org/0000-0001-8927-2683</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2021-12, Vol.16 (12), p.e0261194-e0261194 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_2610899942 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Adult Aged Animal models Antibiotics Antibodies Arachnids Biology and Life Sciences Biopsy Biosynthesis Borrelia Borrelia burgdorferi Group - drug effects Borrelia burgdorferi Group - isolation & purification Borreliosis Care and treatment Cholesterol Clinical trials Diagnosis Dosage and administration Enrollments Erythema Erythema Chronicum Migrans - drug therapy Erythema Chronicum Migrans - epidemiology Erythema Chronicum Migrans - microbiology Erythema Chronicum Migrans - pathology Female Follow-Up Studies Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Immunology Infectious diseases Laboratories Lyme Disease - drug therapy Lyme Disease - epidemiology Lyme Disease - microbiology Lyme Disease - pathology Male Medical ethics Medicine Medicine and Health Sciences Middle Aged Patients Prospective Studies Research and Analysis Methods Signs and symptoms Skin - drug effects Skin - microbiology Skin - pathology Spirochetes Statins Testing |
| title | Association between statin use and clinical course, microbiologic characteristics, and long-term outcome of early Lyme borreliosis. A post hoc analysis of prospective clinical trials of adult patients with erythema migrans |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T23%3A00%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20between%20statin%20use%20and%20clinical%20course,%20microbiologic%20characteristics,%20and%20long-term%20outcome%20of%20early%20Lyme%20borreliosis.%20A%20post%20hoc%20analysis%20of%20prospective%20clinical%20trials%20of%20adult%20patients%20with%20erythema%20migrans&rft.jtitle=PloS%20one&rft.au=Stupica,%20Da%C5%A1a&rft.date=2021-12-16&rft.volume=16&rft.issue=12&rft.spage=e0261194&rft.epage=e0261194&rft.pages=e0261194-e0261194&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0261194&rft_dat=%3Cgale_plos_%3EA687101227%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2610899942&rft_id=info:pmid/34914751&rft_galeid=A687101227&rft_doaj_id=oai_doaj_org_article_c8ab41efd26d4b4a9d19966dc93c1708&rfr_iscdi=true |